Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depleti1
Washington University School of Medicine
Pediatric Hematologic Malignancies
This single arm pilot phase I study with safety run-in is designed to estimate the safety
and efficacy of a familial mismatched or haploidentical hematopoietic stem cell
transplantation (haplo-HSCT) using a novel graft modification technique (selective αβ-TCR
and CD19 depletion). expand
This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a novel graft modification technique (selective αβ-TCR and CD19 depletion). Type: Interventional Start Date: Nov 2022 |
|
Role of KATP Channel Loss in Type 2 Diabetes
Washington University School of Medicine
Obesity and Type 2 Diabetes
Insulin is a hormone that is made by β-cells in the pancreas and when released into the
bloodstream helps control blood sugar levels. Insulin release is regulated by electrical
activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel.
While reduced KATP activity is as1 expand
Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 diabetes. Intriguingly, evidence from cell and animal models suggest that chronically stimulated β-cells can lose KATP revealing a possible role for KATP loss in the failure of insulin secretion and poor control of blood sugar observed in type 2 diabetes. This study will therefore examine insulin responses following ingestion of a single dose of a sulfonylurea called glipizide that inhibits KATP channels in people with and without type 2 diabetes. The goal is to determine whether KATP channel activity is reduced during type 2 diabetes progression. Type: Interventional Start Date: Mar 2025 |
|
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vapi1
Washington University School of Medicine
Nicotine Vaping
Nicotine Use Disorder
Use of vaping products (e.g., electronic nicotine delivery systems, e-cigarettes) has
been increasing rapidly, particularly among teens and young adults. With limited
information on the long-term effects of vaping products, health information about vaping
has been somewhat unclear in regards to ass1 expand
Use of vaping products (e.g., electronic nicotine delivery systems, e-cigarettes) has been increasing rapidly, particularly among teens and young adults. With limited information on the long-term effects of vaping products, health information about vaping has been somewhat unclear in regards to associated health risks. Teens and young adults may be reluctant to disclose their use of vaping products to parents or health providers and instead turn to social media to share and seek out information regarding vaping risks and cessation supports. Thus, our current proposal outlines the use of social media to identify teens and young adults socially networking about vaping, the use of an online chatbot screen to evaluate individual cessation support needs, and the use of a digital intervention system to support vaping cessation. The mobile intervention used in this study is based on a widely-used evidence-based mobile intervention for combustible smoking (i.e., quitSTART) and has been adapted for vaping and young adults to include an in-app chatbot to guide users to tailored content and to motivate and encourage their cessation efforts. We aim to integrate our social media recruitment and online screening approach to connect individuals with this mobile app intervention, and will conduct a randomized controlled trial to evaluate user engagement with and preliminary efficacy of the digital intervention on reducing vaping behaviors among teens and young adults. Type: Interventional Start Date: Jun 2025 |
|
Examining Racial and Socioeconomic Differences in Chronic Low Back Pain
Washington University School of Medicine
Chronic Pain
The purpose of this research study is to gain a better understanding of how people's
racial background and socioeconomic status (e.g., income, education, and employment)
impact their experiences of chronic low back pain (cLBP). expand
The purpose of this research study is to gain a better understanding of how people's racial background and socioeconomic status (e.g., income, education, and employment) impact their experiences of chronic low back pain (cLBP). Type: Observational Start Date: Apr 2024 |
|
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III1
Washington University School of Medicine
Breast Cancer
Cancer of the Breast
This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant
treatment selection. It is the hypothesis that this will improve clinical response for
postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer
and identify those who may not require ne1 expand
This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients. Type: Interventional Start Date: May 2024 |
|
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma1
Polaris Group
Soft Tissue Sarcoma
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously
treated with an anthracycline. expand
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline. Type: Interventional Start Date: Nov 2023 |
|
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Canc1
Washington University School of Medicine
Breast Cancer
Cancer of Breast
Breast Neoplasms
Cancer of the Breast
Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors
can be identified. These trials have also demonstrated that there are not adverse effects
on overall outcome if women are treated with neoadjuvant endocrine therapy for several
months prior to definitive treatme1 expand
Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with neoadjuvant endocrine therapy for several months prior to definitive treatment. A new standard of care needs to be defined for elderly women with good prognosis estrogen receptor (ER)+ tumors, since these women may benefit from endocrine therapy alone to treat their cancer without compromising local and distant control. The investigators hypothesize that endocrine therapy alone provides adequate local and systemic control of breast cancer in a subpopulation of women 70 or older with ER+ breast cancer and low Ki67 scores. Type: Interventional Start Date: Jan 2017 |
|
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Cure HHT
Hereditary Hemorrhagic Telangiectasia
Arteriovenous Malformations
Telangiectasia
Epistaxis
GastroIntestinal Bleeding
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational
registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The
purpose of this study is to better understand HHT, the symptoms and complications it
causes, and the impact the disease has1 expand
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease. Another important goal of the study is to provide a way to contact people to participate in future clinical trials and other research. The registry will be a centralized resource for recruitment for clinical trials. People in the registry will not be obligated to join any of these additional studies, but if interested, can agree to be contacted if they may be eligible for a study. Participants will: - Be asked to provide permission to collect information from their medical records, including things like demographic information, diagnosis information, family history, test results, treatment information, symptoms, complications, lifestyle and other relevant medical information. - Be asked study-related questions by phone or at a clinic visit. - Be asked study-related questions every year after enrollment for up to 10 years or until the study ends. A member of the study team will communicate with participants by phone or at clinic visits to collect information regarding any changes to their health over the previous year/s including new test results, treatment information, symptoms, and complications from HHT. Type: Observational [Patient Registry] Start Date: Nov 2023 |
|
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
University of Utah
Hydrocephalus
Hydrocephalus is a potentially debilitating neurological condition that primarily affects
babies under a year of age and has traditionally been treated by inserting a shunt
between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt-
free treatment that may reduce complicat1 expand
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectual outcome and brain structural integrity between these two treatments, to help families make the best treatment decision for their baby. Type: Interventional Start Date: Jul 2020 |
|
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
Joseph Broderick, MD
Intracerebral Hemorrhage
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time
(FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral
hemorrhage (ICH) within a time window and subgroup of patients that is most likely to
benefit. The central hypothesis is tha1 expand
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 90 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include those treated within 2 hours with a positive spot sign on a baseline CT angiogram or patients treated within 90 minutes of stroke onset, with or without a positive spot sign. Type: Interventional Start Date: May 2025 |
|
Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA
Bolton Medical
Abdominal Aortic Aneurysms (AAA)
The goal of this clinical trial is to learn if the Fenestrated TREO Stent-Graft System
works to treat abdominal aneurysms in adults. An abdominal aneurysm is a bulge in the
main blood vessel (the aorta) which carries blood from the heart, through the chest and
abdomen. It will also learn about the1 expand
The goal of this clinical trial is to learn if the Fenestrated TREO Stent-Graft System works to treat abdominal aneurysms in adults. An abdominal aneurysm is a bulge in the main blood vessel (the aorta) which carries blood from the heart, through the chest and abdomen. It will also learn about the safety of Fenestrated TREO Stent-Graft System. The main question it aims to answer is: Can the the Fenestrated TREO Stent-Graft System be used to treat participants with a specific type of abdominal aneurysm called a juxtarenal abdominal aortic aneurysm? Participants will: Have the the Fenestrated TREO Stent-Graft System implanted via an endovascular surgical procedure and visit the hospital for a follow up period of 5 years, for checkups, tests and imaging scans. Type: Interventional Start Date: Nov 2025 |
|
Evaluation of a Novel Technology to Support Tailored Health Behavior Counseling in Rural Primary Ca1
Washington University School of Medicine
Cardiovascular Diseases
Obesity
This project will conduct a pilot hybrid study that examines the implementation (Aims 1 &
2) and preliminary effectiveness (Aim 3) of PREVENT, a digital health intervention, among
patients with overweight/obesity (N=100) using a clinic-randomized design. The central
hypothesis of the study is that1 expand
This project will conduct a pilot hybrid study that examines the implementation (Aims 1 & 2) and preliminary effectiveness (Aim 3) of PREVENT, a digital health intervention, among patients with overweight/obesity (N=100) using a clinic-randomized design. The central hypothesis of the study is that PREVENT will be feasible and show improvements in health behavior counseling and the patient experience that will improve patients' motivation to change, and their CVH health behaviors and outcomes. Type: Interventional Start Date: Nov 2024 |
|
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluati1
Varian, a Siemens Healthineers Company
Tachycardia, Ventricular
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy
between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter
ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who
have experienced VT recurrence after CA and1 expand
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA. Type: Interventional Start Date: Apr 2023 |
|
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventiv1
SWOG Cancer Research Network
Extensive Stage Lung Small Cell Carcinoma
Limited Stage Lung Small Cell Carcinoma
Lung Small Cell Carcinoma
This phase III trial studies magnetic resonance imaging (MRI) surveillance and
prophylactic cranial irradiation (PCI) to see how well they work compared to MRI
surveillance alone in treating patients with small cell lung cancer. MRI scans are used
to monitor the possible spread of the cancer with a1 expand
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans. Type: Interventional Start Date: May 2020 |
|
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metas1
Regor Pharmaceuticals Inc.
Breast Cancer
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety,
tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B
administered orally as monotherapy OR in combination with Hormonal Therapy in subjects
with HR+, HER2- locally advanced and unresectable1 expand
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy. Type: Interventional Start Date: Mar 2022 |
|
Aging, Geriatric Syndromes and Clonal Hematopoiesis
Washington University School of Medicine
Geriatrics
Aged
Geriatric Syndromes
Cardiovascular Diseases
In this study the investigators will incorporate a wide range of clinical variables
associated with aging and cardiovascular disease to determine whether they are associated
with mutation status independent of chronologic age. Clinically, aging can be
operationalized using geriatric assessment, whi1 expand
In this study the investigators will incorporate a wide range of clinical variables associated with aging and cardiovascular disease to determine whether they are associated with mutation status independent of chronologic age. Clinically, aging can be operationalized using geriatric assessment, which entails a comprehensive multi-dimensional assessment of the health of an older adult, including measures of comorbidity, polypharmacy, functional status, cognition, depression, falls, social activities and social support. Given that aging is heterogeneous, geriatric assessment allows greater specificity for aging than chronological age alone. Type: Observational Start Date: Mar 2016 |
|
Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving P1
Washington University School of Medicine
Central Nervous System
This study will explore neurocognitive performance in pediatric brain tumor patients
receiving proton beam radiation therapy (PBRT). The investigators goal is to gather
baseline neurocognitive testing prior to the completion of the first week of radiation
therapy along with follow-up testing 6-12 m1 expand
This study will explore neurocognitive performance in pediatric brain tumor patients receiving proton beam radiation therapy (PBRT). The investigators goal is to gather baseline neurocognitive testing prior to the completion of the first week of radiation therapy along with follow-up testing 6-12 months after the completion of radiation and serial annual testing thereafter. With these data the investigators plan to evaluate the effects of PBRT on neurocognitive performance as it relates to patients' age at diagnosis, tumor location, and radiation dose. Modeling studies have demonstrated that PBRT could improve neurocognitive outcomes, but there is a paucity of prospectively-collected patient data. The investigators are uniquely positioned to address this important question given the busy pediatric central nervous system (CNS) tumor service, the delivery of proton therapy at the S. Lee Kling Proton Therapy Center at Barnes-Jewish Hospital, and the multi-disciplinary research team with extensive experience into the late effects of therapy as it relates to neurocognition. Type: Observational Start Date: Oct 2015 |
|
LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Palli1
Washington University School of Medicine
Syphilis Infection
Benzathine Penicillin Adverse Reaction
There is evidence to suggest that lidocaine can help reduce the pain associated with
intramuscular injections of benzathine penicillin G (BPG) or Bicillin, used to treat
syphilis infections. A study published in the Journal of Family Practice in 2001 compared
the pain experienced during bicillin in1 expand
There is evidence to suggest that lidocaine can help reduce the pain associated with intramuscular injections of benzathine penicillin G (BPG) or Bicillin, used to treat syphilis infections. A study published in the Journal of Family Practice in 2001 compared the pain experienced during bicillin injections with and without the use of lidocaine. The study found that patients who received lidocaine injections before receiving bicillin reported significantly less pain compared to those who received bicillin injections without lidocaine. Per the International Union against Sexually Transmitted Infections (IUSTI) European Guidelines for syphilis management, lidocaine has been used as a diluent for BPG since 1998. In the United States (US), BPG often comes prepackaged and lidocaine is unable to be used as a diluent with the same ease as it is in Europe. In light of this, the investigators propose a randomized controlled trial of benzathine penicillin G with and without lidocaine to quantify any site pain reduction with lidocaine in patients being treated for syphilis. This study is a randomized, double blinded, placebo controlled trial. During this study, patients needing BPG treatment for syphilis will be screened for any penicillin allergies and consented to their participation. Each participant will receive 2 injections of BPG, 1.2 million units each (2x1.2 million units = 2.4 million units, the standard dose for syphilis treatment), as intramuscular injections, one in each gluteal muscle, with one of the injections randomly having 0.5ml of 1% lidocaine added while the other has 0.5 ml normal saline solution. The side of each injection will be randomized by the medical assistant (MA)/nurse filling the vials and the injecting MA will be blinded, as well as the study participant, as to which vial contains lidocaine and which contains normal saline. The participants will then be asked to rate their pain from 0-10 on each site of injection at 10 minutes post injection, then again at 24 hours after injection via email electronic survey (via RedCap). The differences in pain from the two injections will be compared and analyzed to see if lidocaine reduces pain associated with BPG injections compared to the control of normal saline added to BPG. Type: Interventional Start Date: Jul 2024 |
|
CANF-Comb-II PET-MR in Atherosclerosis Multisite
Washington University School of Medicine
Carotid Atherosclerosis
Asymptomatic Carotid Artery Stenosis
Carotid Artery Atheroma
The goal of this observational study is to learn more about plaque biology in
asymptomatic carotid artery stenosis (ACAS) patients through imaging. The main questions
it aims to answer are:
- To determine the ability of 64Cu-CANF-Comb positron emission tomography (PET) to
risk stratify ACA1 expand
The goal of this observational study is to learn more about plaque biology in asymptomatic carotid artery stenosis (ACAS) patients through imaging. The main questions it aims to answer are: - To determine the ability of 64Cu-CANF-Comb positron emission tomography (PET) to risk stratify ACAS patients for stroke event, to include transient ischemic attack or remote ipsilateral intervention. - To further understand the role of Natriuretic Peptide Receptor C (NPRC) in the evolution of carotid atherosclerosis. Participants will be asked to undergo a carotid PET-magnetic resonance imaging (MRI) examination to assess whether the carotid atherosclerosis uptake of 64Cu-CANF-Comb as measured by PET-MRI correlates with patient outcomes (stroke, transient ischemic attack, or remote ipsilateral intervention). Type: Observational Start Date: Mar 2023 |
|
Cannabis, HIV and Mental Processing Systems
Washington University School of Medicine
HIV Infections
Cannabis
This study employs novel methods to identify key determinants and consequences of
concurrent HIV infection and regular cannabis use. This study will acquire extensive
phenotype data from peripheral and brain markers of immune activation, brain structure,
and neuropsychological performance (NP) in p1 expand
This study employs novel methods to identify key determinants and consequences of concurrent HIV infection and regular cannabis use. This study will acquire extensive phenotype data from peripheral and brain markers of immune activation, brain structure, and neuropsychological performance (NP) in persons living with HIV (PLWH) receiving combination anti-retroviral therapy (cART) (80 regular cannabis users and 80 non-users) and HIV uninfected (HIV-) controls (80 regular cannabis users and 80 non-users). This study will provide key insights into the effects of regular cannabis and HIV on peripheral and brain markers of immune function and NP in PLWH and HIV- controls. These insights are critical for cure strategies and ongoing HIV treatment initiatives. Type: Observational Start Date: Mar 2022 |
|
Investigations of Dementia in Parkinson Disease
Washington University School of Medicine
Parkinsons
The purpose of this study is to use a brain imaging method called Pittsburgh B (PIB)
Positron Emission Tomography (PET) and Vesicular Cholinergic Transport (VAT) PET to
determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of
this project is to be able to identify i1 expand
The purpose of this study is to use a brain imaging method called Pittsburgh B (PIB) Positron Emission Tomography (PET) and Vesicular Cholinergic Transport (VAT) PET to determine dementia subtypes in patients with Parkinson disease (PD). The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia. Type: Observational Start Date: Jun 2016 |
|
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
Implicit Bioscience
STEMI
STEMI (ST Elevation MI)
STEMI - ST Elevation Myocardial Infarction (MI)
Stent Implantation
Adults who have had an ST-elevation myocardial infarction and were treated with stent
placement will receive an intravenous infusion of a monoclonal antibody in order to
prevent further heart muscle damage. The goal is to learn if this treatment improves some
measures of heart function and inflamma1 expand
Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment). Type: Interventional Start Date: Feb 2025 |
|
Maternal Maneuvers During Prolonged Labor
Washington University School of Medicine
Labor Stage, First
Prolonged Labor
This pilot, randomized control trial will test whether or not a specific circuit of
position changes improves maternal outcomes in cases of prolonged labor.
Patient who have prolonged labor will be approached for consent and randomization to one
of two study groups: circuit intervention against ro1 expand
This pilot, randomized control trial will test whether or not a specific circuit of position changes improves maternal outcomes in cases of prolonged labor. Patient who have prolonged labor will be approached for consent and randomization to one of two study groups: circuit intervention against routine standard of care position changes. 82 patients will be enrolled in the study. Exclusion criteria will include: any uterine infection prior to randomization, magnesium sulfate treatment, major fetal anomalies, BMI ≥50, non-reassuring fetal status prior to randomization, or any maternal diagnosis that precludes safety or feasibility of the circuit of maternal position changes. The 3 aims of the study will include: the outcome that the circuit of position changes has on the duration of the first stage of labor, maternal and neonatal morbidity, and maternal satisfaction. Type: Interventional Start Date: Dec 2024 |
|
Chromosome 9 P Minus Syndrome
Washington University School of Medicine
Chromosome 9P Deletion Syndrome
9p Minus Syndrome
Alfi Syndrome
9P Monosomy
9P Partial Monosomy Syndrome
Patients with deletion of chromosome 9 P are rare (~200 in the medical literature) and
have a diverse set of phenotypic characteristics. We propose using state of the art
genome sequencing methods to define the location and size of the deleted portion of
chromosome 9 P as well as the genetic backgr1 expand
Patients with deletion of chromosome 9 P are rare (~200 in the medical literature) and have a diverse set of phenotypic characteristics. We propose using state of the art genome sequencing methods to define the location and size of the deleted portion of chromosome 9 P as well as the genetic background in affected patients (whole genome sequencing) and correlate the genes in the deleted portion of chromosome 9 P with specific phenotypic characteristics of each patient. Enrolled participants will be asked to complete a detailed questionnaire, complete a medical release form, and provide a biospecimen sample. Type: Observational Start Date: Jun 2017 |
|
F 18 T807 Tau PET Imaging of Alzheimer's Disease
Tammie L. S. Benzinger, MD, PhD
Alzheimer Disease
A single-center, open-label baseline controlled imaging study designed to assess whether
brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive
status of individuals with and without brain tau fibrils. expand
A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils. Type: Observational Start Date: Oct 2014 |